ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO102

Canagliflozin Improves Renal Oxidative Stress and Inflammation in Ischemia-Reperfusion Syndrome in Rats

Session Information

  • AKI: Mechanisms - III
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Vattimo, Maria de Fatima F., Universidade de Sao Paulo, Sao Paulo, Brazil
  • Ventura, Sara, Universidade de Sao Paulo, Sao Paulo, Brazil
  • Silva, Eloiza Oliveira, Universidade de Sao Paulo, Sao Paulo, Brazil
  • Debbas, Victor, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil

Group or Team Name

  • Experimental Research Group on Acute Kidney Injury

Recent studies have shown that sodium-glucose cotransporter 2 (SGLT-2) inhibitors alleviate acute kidney injury (AKI) in diabetic patients. Ischemia-reperfusion (I/R) syndrome is the most relevant cause of AKI. Several molecular mechanisms, including oxidative stress as well as the inactivation of anti-inflammatory pathways such as Nrf2, contribute to the I/R syndrome. The aim of this study is to investigate the renoprotective effect of canagliflozin on I/R syndrome in non-diabetic rats.


Wistar rats were divided into: SHAM: surgery control; I/R: ischemic group (30 minute bilateral renal clamping); CANA: canagliflozin (30 mg/kg, once, daily, 5 days); CANA+I/R: as described. Renal hemodynamics such as renal blood flow (RBF) and renal vascular resistance (RVR); renal function (inulin clearance, plasma creatinine); oxidative metabolites (urinary peroxides, TBARS, urinary nitrate and thiols in renal tissue) and Nrf2 were analyzed.


[Figure 1] [Figure 2]


Canagliflozin did not induce hypoglycemia and has significant potential as a therapeutic intervention to ameliorate renal injury after renal I/R and attenuate oxidative stress and inflammation.

Figure 1. Hemodynamics, renal function and oxidative estress.
Values shown are mean±SE: a p<0,05 versus SHAM; b p<0,05 versus CANA; c p<0,05 versus I/R were significantly different as indicated; one way ANOVA followed by Tukey's pos test were performed.

Figure 2. Densitometry of Nrf2. I/R syndrome can inhibit the Nrf2 pathway.


  • Government Support – Non-U.S.